Photo of smiling man with short beard

BLENREP dosing & administration

BLENREP offers an off-the-shelf B-cell maturation antigen (BCMA)- targeting monotherapy with a short infusion time for patients with triple-class refractory multiple myeloma

For GB healthcare professionals only.*

Table of contents

BLENREP offers a straightforward dosing regimen.
The recommended dose of BLENREP is:1

Infographic outlining the dosing and administration regimen for BLENREP

Treatment should be continued until disease progression or unacceptable toxicity.1

Learn more about BLENREP side effects

VIEW SAFETY DATA

BLENREP adverse events (AEs) can be managed through dose delays and modifications so you can keep your patient on treatment1

Category* Eye examination findings Recommended dose modifications
Mild

Corneal examination finding(s)

Mild superficial keratopathy

Continue treatment at current dose.

Change in BCVA

Decline from baseline of 1 line on Snellen Visual Acuity

Moderate

Corneal examination finding(s)

Moderate superficial keratopathy

Withhold treatment until improvement in examination findings and BCVA to mild severity or better.

Consider resuming treatment at a reduced dose of 1.9 mg/kg.

Change in BCVA

Decline from baseline of 2 or 3 lines (and Snellen Visual Acuity not worse than 20/200)

Severe

Corneal examination finding(s)

Severe superficial keratopathy§

Corneal epithelial defect

Change in BCVA

Decline from baseline of more than 3 lines

Withhold until improvement in examination findings and BCVA to mild severity or better.

For worsening symptoms that are unresponsive to appropriate management, consider discontinuation.

Adapted from BLENREP SmPC.
BVCA, best-corrected visual acuity.

*The severity category is defined by the most severely affected eye as both eyes may not be affected to the same degree.1
Mild superficial keratopathy (documented worsening from baseline), with or without symptoms.1
Moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity.1
§Severe superficial keratopathy with or without diffuse microcyst-like deposits involving the central cornea, sub-epithelial haze (central), or a new central stromal opacity.1
A corneal defect may lead to corneal ulcers. These should be managed promptly and as clinically indicated by an eye care professional.1

Adverse reaction Severity Recommended dose modifications
Thrombocytopenia Grade 2–3: Platelet count 25,000 to less than 75,000/microlitres Consider withholding BLENREP and/or reducing the dose of BLENREP to 1.9 mg/kg.

Grade 4: Platelet count less than 25,000/microlitres

Withhold BLENREP until platelet count improves to Grade 3 or better. Consider resuming at a reduced dose of 1.9 mg/kg.
Infusion-related reactions

Grade 2 (moderate)

Interrupt infusion and provide supportive treatment. Once symptoms resolve, resume at lower infusion rate by at least 50%.

Grade 3 or 4 (severe)

Interrupt infusion and provide supportive treatment. Once symptoms resolve, resume at lower infusion rate by at least 50%. If anaphylactic or life-threatening infusion reaction, permanently discontinue the infusion and institute appropriate emergency care.

Adapted from BLENREP SmPC.

Adverse reactions were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).

With BLENREP, 88% of responses were sustained or deepened, despite prolonged dose delays2

Clinical outcomes in patients from the DREAMM-2 clinical trial with ≥1 prolonged dose delays (≥3 treatment cycles) during the first prolonged delay:2

  BLENREP, 2.5 mg/kg (n=16)
Maintaned a clinical benefit, n (%) 14 (88)
Deepend clinical response 6 (38)
Maintained the same response category 6 (38)
Did not meet progression criteria* 2 (13)
Developed progressive disease, n (%) 2 (13)

Adapted from Lonial S, et al. Cancer. 2021.

Percentages do not add up to 100% due to rounding.
*Indicates patients with elevated paraproteins reported during the delays, though these elevated paraproteins did not meet progressive disease criteria.2
One patient developed progressive disease 6 weeks into delay and one patient developed progressive disease 3 weeks after delay.2

Most patients continued to experience a clinical benefit during the delay, and some even deepened their response, hence enabling effective AE management without compromising disease control.2

Dig deeper into BLENREP with our resources library

VIEW RESOURCES

*BLENREP is not commercially available in Northern Ireland.

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1

Abbreviations

AE, adverse event; BCMA, B cell maturation antigen; BCVA, best corrected visual acuity; SmPC, Summary of Product Characteristics.

References

  1. BLENREP Summary of Product Characteristics.
  2. Lonial S, et al. Cancer. 2021;127(22):4198–4212.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

October 2022 | PM-GB-BLM-WCNT-220006 (V1.0)